Defibrotide for Protecting Against and Managing Endothelial Injury in Hematologic Malignancies and COVID-19

Defibrotide for Protecting Against and Managing Endothelial Injury in Hematologic Malignancies and COVID-19

Defibrotide, which is approved for treating hepatic veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS), exhibits pleiotropic anti-inflammatory, anti-thrombotic, and fibrinolytic properties, conferring broad endothelial protective effects. Given these mechanisms, defibrotide has poten...

Full description

Saved in:
Bibliographic Details
Main Authors: Edward Richardson, Clifton C. Mo, Eleonora Calabretta, Francesco Corrado, Mehmet H. Kocoglu, Rebecca M. Baron, Jean Marie Connors, Massimo Iacobelli, Lee-Jen Wei, Emily J. Benjamin, Aaron P. Rapoport, Maribel Díaz-Ricart, Antonio José Martínez-Mellado, Carmelo Carlo-Stella, Paul G. Richardson, José M. Moraleda
Format: Article
Language:English
Published: MDPI AG 2025-07-01
Series:Biomolecules
Subjects:
CAR T-cell therapy
bispecific antibodies/bispecific T-cell engagers
COVID-19
CRS
endotheliitis
endotheliopathy
Online Access:https://www.mdpi.com/2218-273X/15/7/1004
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2218-273X/15/7/1004

Similar Items